Tonse Pamodzi: Developing a combination strategy to support adherence to antiretroviral therapy and HIV pre-exposure prophylaxis during pregnancy and breastfeeding.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 22 12 2020
accepted: 01 06 2021
entrez: 25 6 2021
pubmed: 26 6 2021
medline: 18 11 2021
Statut: epublish

Résumé

To eliminate mother-to-child transmission of HIV (EMTCT), scalable strategies to enhance antiretroviral adherence for both antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are needed as part of integrated HIV and maternal-child health services. We developed Tonse Pamodzi ("all of us together"), an adaptable intervention integrating biomedical and behavioral components to support HIV treatment and prevention. We describe our intervention development process, which comprised formative qualitative research, a review of the literature, and technical input from stakeholders representing the community, health systems, and policymakers. The resulting intervention, described herein, integrates patient-centered counseling and engagement of a patient-selected adherence supporter for pregnant and breastfeeding women initiating ART or PrEP. Patients receiving the intervention engage in Integrated Next Step Counseling (iNSC) sessions delivered by trained counselors to build and maintain adherence skills. Each patient also has the option of selecting an adherence supporter (partner, family member, or friend) who may participate in iNSC sessions and provide adherence support outside of these sessions. This flexible intervention is adaptable not only to ART or PrEP use, but also to the needs and preferences of each woman and the clinical context. If shown to be acceptable and feasible, the Tonse Pamodzi intervention may be an important tool in continuing efforts for EMTCT.

Identifiants

pubmed: 34170913
doi: 10.1371/journal.pone.0253280
pii: PONE-D-20-40105
pmc: PMC8232532
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0253280

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI120796
Pays : United States
Organisme : NIMH NIH HHS
ID : R00 MH104154
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131060
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH121186
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States

Déclaration de conflit d'intérêts

LMH reports grant support from Gilead Sciences. KRA reports consulting for Gilead Sciences in two expert advisory meetings (December 2020 and June 2021). This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors otherwise have declared that no competing interests exist.

Références

Open Forum Infect Dis. 2018 May 02;5(6):ofy097
pubmed: 29977957
AIDS. 2014 Feb 20;28(4):589-598
pubmed: 24468999
AIDS Behav. 2019 Jul;23(7):1812-1823
pubmed: 30315429
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
AIDS Behav. 2011 Nov;15(8):1795-802
pubmed: 21424272
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25521
pubmed: 32603025
Soc Sci Med. 2000 Sep;51(6):843-57
pubmed: 10972429
BMJ. 2010 Dec 22;341:c6580
pubmed: 21177735
Bull World Health Organ. 2018 Jan 1;96(1):69-71
pubmed: 29403103
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S78-87
pubmed: 22797744
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):259-265
pubmed: 28777265
J Int AIDS Soc. 2017 Mar 22;20(1):21371
pubmed: 28630651
Health Psychol. 2004 Mar;23(2):207-18
pubmed: 15008666
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S111-S114
pubmed: 28498179
Health Psychol. 2008 Mar;27(2):159-69
pubmed: 18377134
J Acquir Immune Defic Syndr. 2010 May 1;54(1):85-92
pubmed: 20418724
Curr HIV/AIDS Rep. 2013 Jun;10(2):124-33
pubmed: 23440538
PLoS One. 2019 Jul 26;14(7):e0219967
pubmed: 31348782
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
J Health Psychol. 2011 Oct;16(7):1071-81
pubmed: 21459919
PLoS One. 2011;6(6):e21020
pubmed: 21695214
AIDS Behav. 2012 Jul;16(5):1243-59
pubmed: 22460228
AIDS Care. 2012;24(5):583-92
pubmed: 22292452
MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51
pubmed: 23446514
Lancet. 1992 Sep 5;340(8819):585-8
pubmed: 1355163
N Engl J Med. 1991 Aug 29;325(9):593-8
pubmed: 1812850
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
Curr HIV/AIDS Rep. 2020 Oct;17(5):422-430
pubmed: 32725317
BMC Infect Dis. 2019 Sep 16;19(Suppl 1):789
pubmed: 31526366
Curr Opin HIV AIDS. 2016 Jan;11(1):18-26
pubmed: 26417954
PLoS One. 2017 Jun 29;12(6):e0179448
pubmed: 28662036
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S145-53
pubmed: 27355502
Lancet HIV. 2016 Apr;3(4):e175-82
pubmed: 27036993
J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S43-S50
pubmed: 28398996
BMC Pregnancy Childbirth. 2015 May 17;15:117
pubmed: 25982187
MMWR Suppl. 2014 Oct 31;63(4):3-27
pubmed: 25356673
Health Psychol. 2006 Jul;25(4):462-73
pubmed: 16846321
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25293
pubmed: 31321884
Clin Infect Dis. 2016 Nov 1;63(9):1227-1235
pubmed: 27461920
J Int AIDS Soc. 2020 Mar;23(3):e25463
pubmed: 32144874
PLoS One. 2019 Oct 4;14(10):e0223487
pubmed: 31584987
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Int J Inj Contr Saf Promot. 2008 Dec;15(4):221-31
pubmed: 19051085
AIDS. 2020 Apr 1;34(5):761-776
pubmed: 32167990
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8
pubmed: 22267018
BMC Infect Dis. 2018 Nov 16;18(1):581
pubmed: 30445925
AIDS. 2012 Oct 23;26(16):2039-52
pubmed: 22951634
Lancet HIV. 2020 Aug;7(8):e582-e592
pubmed: 32763221
Lancet HIV. 2018 Dec;5(12):e688-e695
pubmed: 30467022

Auteurs

Lauren M Hill (LM)

Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.

Friday Saidi (F)

UNC Project-Malawi, Lilongwe, Malawi.

Kellie Freeborn (K)

Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill, NC, United States of America.

K Rivet Amico (KR)

Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, United States of America.

Nora E Rosenberg (NE)

Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.

Suzanne Maman (S)

Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.

Twambilile Phanga (T)

UNC Project-Malawi, Lilongwe, Malawi.

Mercy Tsidya (M)

UNC Project-Malawi, Lilongwe, Malawi.

Sara Chirwa (S)

UNC Project-Malawi, Lilongwe, Malawi.

Chifundo Zimba (C)

UNC Project-Malawi, Lilongwe, Malawi.

Wilbroad Mutale (W)

Department of Health Policy, University of Zambia School of Public Health, Lusaka, Zambia.

Benjamin H Chi (BH)

Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill, NC, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH